4-methyl-5'-(4-methyl-piperazin-1-yl)-2'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl | 885704-93-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-methyl-5'-(4-methyl-piperazin-1-yl)-2'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl
• 英文别名: 4-Methy-5'-(4-methyl-piperazin-1-yl)-2'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl；1-methyl-4-[5-(4-methylpiperidin-1-yl)-6-nitropyridin-3-yl]piperazine
• CAS: 885704-93-8
• 化学式: C₁₆H₂₅N₅O₂
• 分子量: 319.407
• InChiKey: BXCWEAFYVFXQJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  68.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methyl-5'-(4-methyl-piperazin-1-yl)-2'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 5-(4-Methylpiperazin-1-yl)-3-(4-methylpiperidin-1-yl)pyridin-2-amine
  参考文献：
  名称：

  Discovery of novel FMS kinase inhibitors as anti-inflammatory agents

  摘要：

  The optimization of the arylamide lead 2 resulted in identification of a highly potent series of 2,4-disubstituted arylamides. Compound 8 (FMS kinase IC50 = 0.0008 mu M) served as a proof-of-concept candidate in a collagen-induced model of arthritis in mice. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.059
• 作为产物：
  描述：

  5'-Chloro-4-methyl-2'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl 、 N-甲基哌嗪 在 水 、 乙酸乙酯 、 Sodium sulfate-III 、 silica 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to obtain the title compound (204 mg, 64%)的产率得到4-methyl-5'-(4-methyl-piperazin-1-yl)-2'-nitro-3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl
  参考文献：
  名称：

  Class of arylamide compounds useful as inhibitors of c-fms kinase

  摘要：

  本发明涉及公式I的芳基酰胺和杂环芳基酰胺化合物，其中A、X、R2和W在说明书中阐述，以及其互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I的化合物治疗自身免疫疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、Paget病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移到骨骼。

  公开号：

  US07705042B2

文献信息

• Inhibitors of c-fms kinase
  申请人：Illig R. Carl

  公开号：US20060100201A1

  公开（公告）日：2006-05-11

  The invention relates to compounds of Formula I: wherein A, X, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中A、X、R2和W在说明书中设置，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，它们抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了利用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、Paget病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移至骨骼。
• WO2006/47504
  申请人：——

  公开号：——

  公开（公告）日：——
• US7705042B2
  申请人：——

  公开号：US7705042B2

  公开（公告）日：2010-04-27
• Discovery of novel FMS kinase inhibitors as anti-inflammatory agents
  作者：Carl R. Illig、Jinsheng Chen、Mark J. Wall、Kenneth J. Wilson、Shelley K. Ballentine、M. Jonathan Rudolph、Renee L. DesJarlais、Yanmin Chen、Carsten Schubert、Ioanna Petrounia、Carl S. Crysler、Christopher J. Molloy、Margery A. Chaikin、Carl L. Manthey、Mark R. Player、Bruce E. Tomczuk、Sanath K. Meegalla

  DOI：10.1016/j.bmcl.2008.01.059

  日期：2008.3

  The optimization of the arylamide lead 2 resulted in identification of a highly potent series of 2,4-disubstituted arylamides. Compound 8 (FMS kinase IC50 = 0.0008 mu M) served as a proof-of-concept candidate in a collagen-induced model of arthritis in mice. (c) 2008 Elsevier Ltd. All rights reserved.
• Class of arylamide compounds useful as inhibitors of c-fms kinase
  申请人：Janssen Pharmaceutica NV

  公开号：US07705042B2

  公开（公告）日：2010-04-27

  The invention relates to arylamide and hetereoarylamide compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的芳基酰胺和杂环芳基酰胺化合物，其中A、X、R2和W在说明书中阐述，以及其互变异构体和药学上可接受的盐，其抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I的化合物治疗自身免疫疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏、炎症和神经性疼痛；以及骨质疏松症、Paget病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和肿瘤转移到骨骼。